McPherson T A, Gilpin A, Seland T P
Can Med Assoc J. 1972 Nov 4;107(9):856-9.
Competitive inhibition of binding between radioiodine-labelled encephalitogenic basic protein from human myelin ((125)I-HEProt) and normal human alpha-2 macroglobulin and between (125)I-HEProt and rabbit antiHEProt serum was used to study concentrated cerebrospinal fluid (CSF) under "blind" control for cross-reactivity with HEProt. Samples of CSF from patients meeting the standard criteria for definite MS and possible MS, and from patients with optic neuritis and "other" diagnoses were studied. CSF from patients in all four groups was shown to have an inhibitor cross-reactive with HEProt when studied by the (125)I-HEProt/alpha-2 macroglobulin test, but the amount was significantly greater in the definite MS group than in the "other" group. Results of the two tests on CSF from MS patients correlated, suggesting that the tests were identifying the same inhibitor. It was concluded that CSF contains an inhibitor similar to HEProt and that the amount present in CSF could be a useful diagnostic marker of MS.
利用放射性碘标记的人髓磷脂致脑炎碱性蛋白((125)I-HEProt)与正常人α-2巨球蛋白之间以及(125)I-HEProt与兔抗HEProt血清之间结合的竞争性抑制作用,在“盲法”对照下研究浓缩脑脊液(CSF)与HEProt的交叉反应性。研究了符合明确MS和可能MS标准标准的患者以及患有视神经炎和“其他”诊断的患者的CSF样本。通过(125)I-HEProt/α-2巨球蛋白试验研究发现,所有四组患者的CSF均显示有一种与HEProt交叉反应的抑制剂,但明确MS组中的抑制剂含量明显高于“其他”组。对MS患者CSF进行的两项试验结果相关,表明这两项试验检测的是同一种抑制剂。得出的结论是,CSF中含有一种与HEProt相似的抑制剂,CSF中该抑制剂的含量可能是MS的一种有用诊断标志物。